



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 03/30/2020 11:21

**88888**

Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 0486SP

**Patient ID** 0486SP

**Chain 1**

**Age** Not Given **DOB** Not Given

**Gender** Not Given

**Workorder** 06012180

**Received** 07/25/2006 08:25

**Sample ID** 06012180-001

**Matrix** Serum or Plasma

**Patient Name** 0486SP

**Patient ID** 0486SP

**Container Type** Clear vial

**Collect Dt/Tm** Not Given

**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**0486SP Atomoxetine, Serum/Plasma**

Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)

Atomoxetine	None Detected	ng/mL	10	
Synonym(s):	Strattera®			

Steady-state plasma levels in adults on a chronic 20 mg twice daily regimen:  
35 - 160 ng/mL in extensive metabolizers (normal) and  
500 - 915 ng/mL in poor metabolizers (approximately 7% of Caucasian population).

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.